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ABSTRACT 
The V3 loop of HIV-1 gp120 is an immunodominant region targeted by neutralizing antibodies 
(nAbs). Despite limited breadth, better characterization of the structural details of the interactions 
between these nAbs and their target epitopes would enhance our understanding of the mechanism of 
neutralization and facilitate designing better immunogens to induce nAbs with greater breadth. Recently, 
we isolated two anti-V3 neutralizing monoclonal antibodies (mAbs), 10A3 and 10A37, from a rabbit 
immunized with gp120 of the M group consensus sequence. In this study, crystal structures of these 
mAbs bound to target epitopes were determined. 10A3 binds to the V3 crown (303TRKSIHIGPGRAF317), 
using the cradle binding mode similar to human V3 mAbs encoded by IGHV5-51 germline genes and its 
epitope structure resembles that bound to the human antibodies. In contrast, 10A37, which exhibits 
greater breadth and potency than 10A3, binds the V3 crown and the succeeding stem region 
(307IHIGPGRAFYTTGEII324). Unexpectedly, the 315RAFYTT320 portion of the epitope existed as helical 
turns, a V3 structure that has not been observed previously. Its main chain-dominated antigen-antibody 
interactions not only explain the broad neutralization of 10A37 but also show that its epitope is a potential 
vaccine target to be further evaluated. In conclusion, our study provides novel insights about 
neutralization-susceptible epitope structures of the V3 loop of HIV-1 gp120 and demonstrates that, 
despite low amino acid sequence similarity from human antibody germline genes, rabbits can serve as a 
useful animal model to evaluate human vaccine candidates.  
 
Importance (150 words) 
The apex crown of the third variable loop (V3) of HIV-1 gp120 is the most immunogenic region 
of the surface glycoprotein and many mAbs targeting this region have been developed. Structural 
understanding of V3 crown mAbs not only can help understand how antibody responses targeting this 
unique region, but also contribute to immunogen design for vaccine development. We present here crystal 
structures of two neutralizing V3 mAbs, 10A3 and 10A37, developed from rabbits immunized with 
gp120. Our analysis of 10A3 in complex with V3 provided a detailed example of how epitope complexity 
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can evolve with affinity maturation, while that of 10A37 revealed a novel V3 binding mode targeting the 
C-terminal side of V3 crown and showed that this region can form a helical structure. Our study provides 
novel insights about neutralization-susceptible V3 epitope structures and demonstrates that rabbits can 
serve as a useful animal model to evaluate human vaccine candidates. 
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INTRODUCTION 
 
The third variable loop (V3) of gp120 plays a critical function in viral entry into host cells. It 
determines viral tropism by binding coreceptor CCR5 or CXCR4 (1-4). Linked by a disulfide bond 
between residues 296 and 331 (HXB2 numbering) (5), it is almost always 35 amino acids in length. 
Structurally, the V3 loop can be divided into 3 regions: the crown (residues 304-318), the stem and the 
base regions (6). Despite being variable in sequence, the crown region is structurally quite conserved and 
it often forms a beta hairpin (6-9). The V3 loop is highly immunogenic (10-13) and induces mostly strain-
specific neutralizing antibodies (nAbs). High levels of antibodies targeting the V3 loop have also been 
detected in animals vaccinated with gp120 or V3 peptides (14-18). Many V3 crown-specific monoclonal 
antibodies (mAbs) have been isolated from HIV-1 infected patients (11, 19) and a number of Fab/epitope 
complex structures of them have been determined (20-24, 8, 25, 26), setting the foundation for 
understanding the structural basis of Ab responses against the V3 crown. Sieve analyses of the RV144 
clinical trial indicated that the third variable loop (V3) of HIV-1 envelope glycoprotein gp120 specific 
antibodies correlated with a reduced risk of infection (27, 28), indicating the V3 loop is a potential target 
for HIV vaccine design. 
 The antigen binding modes of human V3 crown mAbs have been shown to fall largely into two 
general categories: cradle or ladle binding modes (24, 8, 25). In the cradle mode, the V3 crown lies along 
an antigen binding groove resembling a cradle. In the ladle mode, the Ab has a long standing CDR H3 
(the handle of the ladle), which interacts with the main chain of the N-terminal beta strand of the V3 
crown and a pocket at the base of the CDR H3 (the bowl of the ladle), which interacts with the apex turn 
of the V3 crown. Data suggested that human V3 crown Abs preferentially use IGHV5-51 germline gene 
(19), and such Abs (e.g. mAb 2557) use the cradle binding mode (8, 25). IGHV3 germline genes are also 
frequently used and some IGHV3-encoded V3 crown Abs (e.g. mAbs 447-52D and 537-10D) use the 
ladle binding mode (21, 29, 24, 30). In both binding modes, the N-terminal strand of the V3 crown plays 
a key role in the antibody-antigen interaction. In the cradle binding mode, the N-terminal strand of the V3 
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crown is buried deep in the antigen binding groove while the C-terminal residues make additional 
contacts with the antibody. In the ladle binding mode, the N-terminal strand of the V3 crown interacts 
with CDR H3 of the antibody and the C-terminal residues are not always observable in the complex 
structures, indicating there is no or very little contacts with the antibody. MAbs isolated from small 
animals immunized with V3 peptides or monomeric gp120 have been shown to be able to mimic human 
mAb binding modes (26). For example, rabbit mAb R56 and mouse mAb 50.1 preferentially recognize 
the V3 crown similar to the cradle binding mode used by human Abs encoded by IGHV5-51 germline 
genes (20, 26). However, the epitopes of these mAbs are shorter and less complex than that of human Ab 
developed from infected patients and their evolution with affinity maturation is not understood. 
We have recently isolated a panel of new V3 loop-specific mAbs from a rabbit immunized with 
gp120 based on the M group consensus sequence (MCON6), and two of them, 10A3 and 10A37, 
exhibited neutralizing activities (16). They target different regions of the V3 loop: 10A3 recognizes a 
peptide consisting of residues RKSIRIGPGQAFYAT (a.a.304-320); 10A37 recognizes a peptide 
consisting of residues RIGPGQAFYATGDII (a.a.308-324), atypical for V3 mAbs. Interestingly, they 
also competed with PGT121, one of the broadly neutralizing mAbs targeting the V3 base glycan patch 
(31, 16). To precisely define the epitopes of these two mAbs and characterize their antigen-antibody 
interactions at atomic level, we determined their Fab/epitope complex structures and compared them with 
V3 specific rabbit mAb R56 (26), and human V3 specific mAbs derived from the IGHV5-51 germline 
gene (8, 25). The results showed that mAb 10A3 targets the V3 crown similar to rabbit mAb R56, but 
makes additional contacts with the C-terminus of the V3 crown region, correlating with additional 
somatic hypermutations. The cradle antigen-binding mode of 10A3 is similar to those of human V3 
specific mAbs derived from the IGHV5-51 gene. In contrast, 10A37 targeted the V3 crown and the 
succeeding stem region, in a new binding mode not observed previously, and its V3 epitope harbors a 
helix core. This study provides novel insights about neutralization-susceptible epitope structures of the 
V3 loop of gp120 and further discerned that rabbit is a useful animal model for the evaluation of the 
immunogenicity of vaccine candidates. 
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METHODS 
Fab production and purification 
MAbs 10A3 and 10A37 were expressed and purified as previously described (16). Briefly, 
plasmids encoding the heavy and light chains were transfected into 293F cells using 293fectin 
(Invitrogen). The cell culture supernatant was collected 5 days after transfection and clarified by 
centrifugation. The mAbs were then purified using protein A column, eluted, and dialyzed in PBS.  
The Fab fragments of rabbit mAbs were prepared by papain digestion as described (24). Briefly, 
the IgG molecule was mixed with papain (Worthington, Lakewood, NJ) at a 20:1 molar ratio in 100 mM 
Tris (pH 6.8) with 1 mM cysteine hydrochloride and 4 mM EDTA. The mixture was incubated for 1 hour 
at 37oC and the reaction was stopped by 10 mM iodoacetamide. The Fab fragment was separated from the 
Fc fragment and the undigested IgG by a protein A column and further purified by size exclusion 
chromatography. The Fab fragment was then concentrated to about 10 mg/ml for crystallization. 
 
Crystallization, data collection, structure determination and refinement 
The V3ConB peptide obtained from NIH AIDS Reagent Program and the V3JR-FL peptide 
synthesized by Biomatik (Wilmington, DE) were dissolved in water and DMSO, respectively, and mixed 
with Fabs 10A3 and 10A37 at a 10:1 molar ratio. Crystallizations conditions were screened and optimized 
using the vapor diffusion hanging drop method. Well-diffracted crystals of 10A3 Fab/V3ConB complex 
were obtained with a well solution of 32% polyethylene glycol 6000, 1 M LiCL, 0.1 M Tris pH 8.0, 
whereas those of the 10A37 Fab/V3JR-FL complex were obtained in a well solution of 18% polyethylene 
glycol 4000, 8.5% Isopropanol, 0.1 M HEPES pH 7.5, 15% glycerol. X-ray diffraction data sets were 
collected at beam line X6A and X4A, National Synchrotron Light Source (NSLS), Brookhaven National 
Laboratory. All data sets were processed using the HKL2000 package (32) and XDS (33), and structures 
determined by molecular replacement using R56 Fab structure (PDB ID 4JO1) as the initial model. 
Cycles of refinement for each model were carried out in COOT (34) and Phenix (35). Coordinates and 
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structure factors of 10A3/V3ConB and 10A37/V3JR-FL complexes have been deposited in the Protein Data 
Bank. 
 
Comparative analyses of rabbit and human mAbs  
Structural analyses were carried out using ICM (36) and figures were generated using PyMOL 
(http://pymol.org). The antigen-antibody interactions described in figures are caculated by ICM and 
PDBePISA (EMBL-EBI). For comparison with rabbit mAbs 10A3 and R56, two V3 human mAbs were 
chosen that are encoded by IGHV5-51 germline genes: mAbs 2219 and 2557 (PDB IDs: 2B0S and 
3MLT). Human antibodies binding to V3 using different binding mode or binding to other parts of the V3 
loop, or to V3 loops with highly dissimilar sequences, have been omitted from this analysis.  
 
RESULTS 
Determination of the complex structure of 10A3/V3ConB 
MAb 10A3 is a chimeric antibody with rabbit variable region and human constant region. The 
peptide used for co-crystallization was selected by screening from a panel of V3 peptides already 
available by ELISA based on the epitope mapping results (16). 10A3 Fab was co-crystallized with a 15-
mer clade B consensus V3 peptide (V3ConB, NNTRKSIHIGPGRAF), which differs from MCON6 gp120 
immunogen at only residue 315 (NNTRKSIHIGPGQAF), which does not play a key role in the antibody 
binding (see below). The crystal of the complex belongs to orthorhombic space group P21221, and the 
complex structure was determined by molecular replacement and refined to 1.9Å resolution (Fig. 1; Table 
1). As there is only one complex in the asymmetry unit, we assigned the chain identities (IDs) of the light 
and heavy chains and the peptide epitope as L, H, and P, respectively. Amino acid residues on the light 
and heavy chains were numbered following the Kabat and Wu convention (37), and V3 residues were 
numbered based on HXB2 scheme. A residue is referred to by its number preceded by its chain ID, for 
example, ArgP315 refers to arginine residue 315 of the peptide epitope. Thirteen V3 residues 
 8 
(303TRKSIHIGPGRAF317) were observed in the electron density and have been built into the final 
structure. 
The complex structure of 10A3/V3ConB shows that 10A3 binds the V3 crown by using the cradle-
binding mode. The antigen-binding pocket is deep and shaped like a cradle with the third 
complementarity determining regions (CDRs) of the light and heavy chains (L3 and H3) situated at each 
end of the cradle (Figs. 1 and 2), and CDRs H1 and H2 forming a wall on one side of the peptide while 
CDRs L1 and L2 on the other side. The periphery of the cradle is negatively charged, contributed by 
GluL50 (L2) and AspL93 (L3) of the light chain on one side, and AspH53 (H2) of the heavy chain on the 
other side (Fig. 1D, Fig. 2A). The bottom of the cradle is hydrophobic, contributed by AlaL91, LeuL89 and 
PheL94, PheH96 and a disulfide bond between CysH35 and CysH50 near CDR H2. Such CDR loop disulfide 
bonds are rarely observed in human Abs but quite frequently in rabbit ones (26, 38).  
 
Detailed antigen-antibody interactions of 10A3/V3ConB 
The antigen-antibody interactions of 10A3 buried a total of 969Å2 surface area with 475Å2 from 
the antibody and 494Å2 from the antigen, involving both hydrophilic and hydrophobic ones. (1) The 
hydrophilic interactions. The side chains of epitope residues, ArgP304 and HisP308, interact directly with 
negatively charge residues of 10A3 at the periphery of the cradle. Specifically, the N-terminal ArgP304 
forms a salt bridge with AspH53 (from CDR H2) and its side chain also stacks with the benzyl group of 
PheP317 that can stabilize its orientation. HisP308 forms also a potential salt bridge with GluL50 (L2). 
Additionally, SerP306 can form hydrogen bonds with the side chain of AsnL32 (L1) and the carbonyl group 
of TyrL28 (L1). The side chain of AsnH95 forms a hydrogen bond with the carbonyl oxygen of HisP308, and 
it has the biggest contact area (~ 50Å2) with the epitope among residues of the heavy chain or the whole 
antibody. (2) The hydrophobic interactions. Several highly conserved residues, including IleP307, IleP309 
and ProP313, of the V3 crown play key roles on the hydrophobic interactions. IleP307 and IleP309 are buried 
into a hydrophobic pocket and the residues of 10A3 that contribute these hydrophobic interactions are 
AlaH33 (H1), CysH50 and AlaH52 (H2) and LeuL89, AlaL91 and PheL94 (L3). ProP313 stacks with two aromatic 
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side chains of TyrH97 and TyrL49 (Fig. 2C). Although 10A3 has a very short four residue CDR H3 (NFYL, 
Kabat definition), it plays several important roles in antigen binding. In addition, PheH96 contributes to the 
hydrophobic pocket burying the two conserved isoleucines, IleP307 and IleP309, of V3 and TyrH97 stacks 
with ProP313 in the arch region of V3. Notably, the backbone of the epitope also involves extensively in 
binding the antibody, and there are six contacts between the backbone of V3 and 10A3 (Figs. 2B and 2C). 
Another point to note is that the side chain of the signature residue ArgP315 (would be Gln in non-clade B 
strains) point away from the antigen binding site, even though it can form a salt bridge with GluL50 (3.6Å). 
 
Determination of the complex structure of 10A37/V3JR-FL 
The Fab of rabbit mAb 10A37, which has a better potency and breadth of neutralizing activity 
than 10A3 does (16), was co-crystallized with a 23-mer JR-FL V3 peptide, 
NNTRKSIHIGPGRAFYTTGEIIG (V3JR-FL; 301-324); its sequence differs from that of MCON6 
immunogen at two positions (NNTRKSIHIGPGQAFYATGEIIG). The complex structure was also 
determined by molecular replacement and refined to 2.3Å resolution (Fig. 3; Table 1). The crystal of the 
complex belongs to monoclinic space group P21, and there are two essentially identical Fab/V3 
complexes in the asymmetry unit (V3 epitope C RMSD = 0.3Å). For simplicity, only one complex is 
used here and the residues are numbered the same way as mentioned above for the 10A3/V3ConB complex 
using L, H, and P for denoting light chain, heavy chain, and V3, respectively. Sixteen residues of V3, 
from 307 to 324 with sequence IHIGPGRAFYTTGEII, were observed in the electron densities and have 
been built into the final structures (Figs. 3 & 4). It is clear that 10A37 has a new mode of binding V3 
crown, different from what have described previously (39, 24, 8, 25). Surprisingly, the epitope of 10A37 
has a helix core (315RAFYTT320), with the N-terminus of the epitope extending straight out on one side of 
the helix core and the C-terminus bent back on the other side. A circular dichroism experiment using a 
full-length cyclic V3 (JR-FL sequence) revealed that it has weakly helical conformation (not shown), 
suggested that some region of V3 may have intrinsic propensity for a helical conformation. Interestingly, 
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the heavy chains of 10A3 and 10A37 are derived from the same rabbit germline gene IGHV1S45*01 
(15), but their CDR H3 lengths are very different: 4 vs 12 residues (Kabat definition), respectively. 
 
Detailed Antigen-antibody interaction of 10A37/V3JR-FL 
The antigen-antibody interactions buried a total of 918Å2 surface area, contributed equally from 
the antibody and the V3 epitope. There are two pockets on the surface of 10A37 antigen binding site (Fig. 
3D): one is ~10Å deep, burying the side chains of PheP317 and TyrP318 from the helix core and another 
shallow one, accommodating ProP313 before the helix. The side chain of IleP323 is also half buried at the 
edge of the deep pocket. Again, we can divide the antigen-antibody interactions into hydrophilic and 
hydrophobic ones. (1) Hydrophilic interactions between the side chains of V3 residues and 10A37 (Fig. 
4A). At the bottom of the deep pocket, AspH95 (of CDR H3) is buried by the side chain of TyrP318; the OH 
group of TyrP318 located between an OD atom of AspH95 (2.63Å) on one side and the OH of TyrL93 (L3; 
2.65Å) on the other side. The side chain of HisP308 at the N-terminal end of the epitope can also form a 
hydrogen bond with the OH group of TyrH100A (H3). (2) Hydrophobic interactions. As aforementioned, 
PheP317 and IleP323, in addition to TyrP318, are buried in a hydrophobic pocket, formed by PheH34 (H1), 
TyrH58 (H2), TryL93 and IleL95D (L3). The aromatic plane of PheP317 is on the top of PheH34 and TryL93, 
while the side chain of IleP323 is on the top of TyrH58 and IleL95D. The V3 arch residue ProP313 is buried in a 
smaller hydrophobic pocket formed by residues GlnL30 (L1), TyrL93 (L3), and TyrH100A (H3). Additional 
contacts between TyrP318 and TryL93 (L3), together with intra-chain interactions between PheP317, IleP323 
and TyrP318, strengthen overall hydrophobic interactions. Interestingly, GlnP315 and AlaP319 of V3 JR-FL, the 
two residues different from the gp120 used as the immunogen to elicit 10A37, only use their backbone to 
contact with antibody. There are eleven main chain interactions between the backbones of V3 and 10A37 
making a notable contribution to the way 10A37 grasps its V3 epitope (Fig. 4B). 
 
Comparison of the antigen-antibody interactions of rabbit V3 mAbs 10A3 and R56 
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The binding mode of 10A3 is very similar to that of another rabbit V3 mAb R56; they both 
recognize the crown of V3, mimicking the cradle-binding mode of human V3 mAbs derived from the 
IGHV5-51 germline gene (Fig. 5) (26). Interestingly, the light chains of 10A3 and R56 are derived from 
the same rabbit light chain germline gene (IGKV1S15*01), although their heavy chains are derived from 
different germlines gene (IGHV1S45*01 and IGHV1S40*01, respectively; Fig. 5C) (15). The light chain 
backbone structures of the two antibodies superimposed remarkably well (C RMSD = 0.5 Å) (Fig. 5A). 
In terms of CDRs, 10A3 and R56 are similar to each other with respect to CDRs H3, L1, L2 and L3. Both 
mAbs have a short 4-residue (Kabat definition) CDR H3 with similar sequence: NFYL (10A3) and NFDL 
(R56). Sequence alignment analyses show the parallel evolution of 10A3 and R56 during affinity 
maturation (Fig. 5C). Within the VL gene, there were six identical mutations on both 10A3 and R56 that 
diverged from the germline sequence (Gly to ValL3, Pro to LeuL4, Thr to SerL25, Glu to GlnL27, Phe to 
ValL27B and Ile to AsnL32; numbering based on 10A3). Within CDR L3, two residues had identical 
mutations (Gln to LeuL89 and His to AspL93). Within the VH gene, four sites had identical mutations (Lys 
to GlnH13, Thr to LysH23, Ala to GlyH49, and Ala to ThrH52A) and one convergent mutation (Ile to MetH34). 
There were many other mutations in the VL gene, however, most of which were not for residues that 
make direct contacts with antigens, suggesting their indirect role in shaping the overall paratope 
conformation. 
Not surprisingly, 10A3 and R56 share many common antigen-antibody interactions using 
identical/similar amino acid residues (Fig. 5C). For the light chain, four of eight positions are conserved, 
including TyrL28, AsnL32, TyrL49, and LeuL89. For the heavy chain, three of six residues are identical 
(CysH50, AsnH95, and PheH96). 10A3 and R56 share the N-terminus and the arch of V3 crown as the 
common epitope region. Two hydrophobic epitope residues IleP307 and IleP309 are buried into hydrophobic 
pockets on the antigen binding sites comprised of CysH50, LeuL89, PheH96, while ProP313 stacks against the 
aromatic plane of TyrL49. In the case of 10A3, the latter interaction is strengthened by TyrH97 that stacks 
against ProP313 on the opposite side of TyrL49. Two main chain interactions are also conserved, including 
IleP307_O and AsnL32_ND2, GlyP312_N and AsnH95_O. Overall, the antigen-antibody interactions are more 
 12 
conserved for the light chain, which play a dominant role in antigen binding for both 10A3 and R56, most 
likely due to their light chains derived from the same germline gene.  
Moreover, the epitope structures of V3 co-crystallized with 10A3 and R56 are very similar (C 
RMSD = 0.9 Å) (Fig. 5B), especially at the N-terminus and the arch of V3 crown, shared epitope region 
of the two mAbs. The side chains also align very well, except for ArgP304 and LysP305. However, 10A3 has 
a longer V3 epitope; it recognizes 13 residues (303TRKSIHIGPGRAF317), while R56 recognizes only 10 
residues (303TRKSIHIGPG314), i.e., 10A3 epitope has an extension of three more C-terminal residues than 
that of R56. Two major factors may have allowed 10A3 to bind the additional three residues: Asp to 
GluL50 and Ser to AspH53 mutations (Figs. 5A and 5C). GluL50 can potentially form an extra salt bridge 
with ArgP315 (distance = 3.6Å) in addition to the close interaction with HisP308 (2.7Å), but the side chain of 
the unmutated germline AspL50 of R56 is too short to interact with ArgP315 (likely > 4Å away). Mutation 
of Ser to AspH53 allows its side chain to form a salt bridge with ArgP304, positioned its guanidinium group 
to stack with the aromatic plane of PheP317, further stabilizing the C-terminal end of the V3 crown. In 
contrast, this is impossible for ArgP304 of V3 forms a buried salt bridge with AspH34 on the surface of R56 
(26). Thus, additional mutations in affinity maturation have introduced V3 contacts in 10A3 that are 
lacking in R56, further stabilized the C-terminal V3 crown region. 
 
Comparison of the antigen-antibody interactions of rabbit 10A3 with human IGHV5-51 encoded 
V3 mAbs 
Crystal structures of several human V3 mAbs derived from IGHV5-51 germline gene have been 
determined, including the mAb 2557, a typical human IGHV5-51 encoded V3 mAb (19, 8, 25). They all 
use the cradle binding mode to bind the V3 crown. The overall conformations of the V3 peptides bound to 
10A3 and 2557 are similar, although the V3 epitope recognized by 2557 is one amino acid longer at the 
C-terminus and forms a rather regular two-stranded anti-parallel beta sheet, whereas the peptide bound to 
10A3 exists as a hairpin coil (Fig. 6A). However, the V3 epitopes of the two antibodies orient nearly 
perpendicular to each other in relationship to their antigen binding sites. The apex arch of V3 crown is 
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laid on top of the CDR H3 when complexed with 10A3, while it points towards the CDR L1 when 
complexed with human mAb 2557. Another difference between the rabbit 10A3 and R56 from that of 
human IGHV5-51 V3 mAb is the extreme short CDR H3; the CHR H3 in the rabbit mAbs is buried under 
the epitope, while the CDR H3 in the human ones forms the wall on one side of the cradle. Nevertheless, 
the epitope structures of V3 co-crystallized with 10A3 and 2557 are similar (C RMSD = 1.58 Å) (Fig. 
6B), especially at the N-terminus and the arch of V3 crown, the common epitope region for both of 
antibodies. The C-terminus of the mAb bound V3 crown was more variable than the N-terminus, which is 
the case of all the human V3 mAbs derived from IGHV5-51 germline gene.  
Structural analyses show the high similarities between rabbit and human V3 mAbs using the 
cradle binding mode in general. There is considerable overlap in the distribution and number of contacts 
formed with the V3 loop by different mAbs (Fig. 6C). A detailed comparison of contact area between the 
epitopes of rabbit mAbs 10A3 and R56 with those of selected human V3 mAbs 2219 and 2557 shows 
their similar recognizing pattern. First, they all focus on the N-terminus of V3 crown and have very few 
contacts with the C-terminus. Second, positively charged residues at the N-terminus of V3 crown play 
key roles on the antigen-antibody interaction. Third, ProP313 in the arch region always stacks against 
aromatic planes. Fourth, V3 residue 315 (often ArgP315 and GlnP315 for clade B and non-clade B strains, 
respectively) does not play a significant role in antibody binding. This also explained that we could 
crystallize 10A3 with ArgP315 while the antibody was induced by a gp120 with GlnP315. In spite of the 
mAb sequence and underlying germline differences, it is clear that the rabbit mAbs can recognize the V3 
crown in similar binding modes as those of the human mAbs.  
 
DISCUSSION 
In this study, we determined and analyzed Fab/peptide complex structures of two recently 
isolated rabbit anti-V3 neutralizing mAbs 10A3 and 10A37, and defined their epitopes at the atomic level. 
Our results showed that 10A3 recognizes the V3 crown region (303TRKSIHIGPGRAF317), and 10A37 
targets the V3 crown and the succeeding stem region (307IHIGPGRAFYTTGEII324). By and large, 10A3 is 
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similar to previously reported rabbit mAb R56, except that its epitope is longer than that of R56 by three 
amino acids at its C-terminal end, resulting in a hairpin structure. In contrast and unlike most of vaccine-
induced V3 specific mAbs, 10A37 targets primarily the C-terminal end of the V3 crown as well as the 
succeeding stem region, a newly observed V3 binding mode. Moreover, its epitope has an -helix core 
that has not been previously observed. Early theoretic prediction suggested that V3 can contain a short 
helix near the C-terminal region of V3 (40), and some NMR studies also reported that C-terminal portions 
of the V3 loop could assume an alpha helical structure in trifluoroethanol/water mixture 
(324IGTIRQAHC332 (41) and 320TGEIIGDIR328 (42)). But these helical conformations were observed in 
unusual buffer conditions and are at downstream of the helical region observed in our crystal structure: 
315RAFYTT320.  
The epitope of 10A3 and its interaction with the V3 crown is an example demonstrating the 
increased complexity of an antibody’s epitope correlating with its affinity maturation (26). In the case of 
rabbit mAb R56, which has a V3 binding mode very similar to 10A3 (Fig. 5), only the first half the V3 
crown was observed when it is in complexed with R56. Since the V3 crown has the propensity to form a 
beta hairpin (6, 43, 9), the C-terminal half of the crown is likely located spatially next to the N-terminal 
half. But R56 has not developed contact that can stabilize the C-terminal half of the V3 crown, it therefore 
could not be observed in the R56/V3 structure. However, in the case of 10A3, contacts have been 
developed through additional somatic hypermutations, and these contacts further stabilize the C-terminal 
half of the V3 crown, allowing it to be observed in 10A3/V3 complex structure. We have only speculated 
previously about this relationship between affinity maturation and the complexity of an antibody’s 
epitope (26), but here we have demonstrated that, by the complex structure of rabbit mAb 10A3, 10A3 
has a binding mode essentially identical to that of R56 but with additional somatic hypermutations. 
Together with R56, our results of 10A3 further support the notion that rabbit antibodies can mimic the 
binding modes of human antibodies, at least against the V3 crown. This similarity is likely predetermined 
by the structure of the V3 crown and its immunogenicity. Human antibodies encoded by IGHV5-51 have 
an antigen binding site that can best accommodate the beta hairpin structure of V3 crown, burying the N-
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terminal half of the V3 crown in the cradle-like binding site. The immunodominance of the V3 crown and 
the ideal shape for the cradle-binding site can then explain the preferential gene usage of IGHV5-51 (19). 
It is then not surprising that rabbit can mount immune responses against the V3 crown and produce 
antibodies with a binding mode similar to those of human antibodies. 
Our structure of the 10A37 complex demonstrate that the C-terminal end of the V3 crown can 
have a helical conformation, different from the commonly observed beta strand. In all the currently 
available Env trimer structures, including the high resolution cryoEM structure of the JR-FL trimer, this 
region has a beta strand conformation, suggesting that the beta strand is the preferred structure in the 
prefusion trimer. However, V3 loop tend to flick out easily (44, 45), and this region may become 
accessible for antibody binding; it can be a vulnerable site for immune responses because the C-terminal 
end of the V3 crown is quite conserved in sequence (8), and possibility of multiple structural 
conformations can be a mechanism for masking this region (46). Our structural data also explain the 
breath of 10A37 in neutralization (Table 2) (16). Although 10A37 has a deep pocket for binding the side 
chains of PheP317 and TyrP318 and is thus side chain specific, these two residues are highly conserved in 
HIV strains (8). In addition, the rest of the antibody/V3 interactions are largely backbone contacts, which 
are not influenced much by sequence variations. Interestingly, 10A3 and 10A37 have similar binding 
affinities (not shown), and we speculate the difference in the breadth is due to the difference in the target 
epitopes. 
In conclusion, our study provides novel insights about neutralization-susceptible epitope 
structures of the V3 loop of gp120 and more evidences that, despite low amino acid sequence similarity 
from human antibody germline genes, rabbits can serve as a useful animal model to evaluate human 
vaccine candidates.  
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FIGURE LEGENDS 
 
FIG 1. Structure of Fab 10A3 in complex with V3ConB. (A) and (B) Ribbon representations of the Fab 
10A3 in complex with V3ConB from two different perspectives. The light and heavy chains are colored 
cyan and green, respectively, while the epitope is colored magenta (The coloring scheme is kept the same 
for all the figures, except where indicated otherwise). (C) The antigen binding site of 10A3 with the CDR 
loops labeled and colored differently from the rest of Fab. (D) Electrostatic potential surface of the 
antigen binding site of 10A3, with the red color indicating negative charged while the blue positively 
charged. Inset: The sequence of the peptide used for crystallization is shown, and residues observed in the 
electron density map are shown in magenta.  
 
FIG 2. Antigen-antibody interactions of 10A3/V3ConB. (A) Hydrophilic interactions between the side 
chains of the epitope and residues of 10A3. (B) Hydrophilic interactions between the main chain of the 
epitope and residues of 10A3. (C) Schematic illustration of antigen-antibody interactions. Hydrogen-
binding interactions are indicated by dashed lines between the residues, while van der Waals contacts are 
indicated by eyelashes. Residues in solid ovals contribute to the interactions by their main chain atoms, 
and those in dashed ovals contribute by their side chain atoms.  
 
FIG 3. Structure of Fab 10A37 in complex with V3JR-FL. (A) and (B) Ribbon representations of the Fab 
10A37 in complex with V3JR-FL from two different perspectives. (C) The antigen binding site of 10A37 
with the CDR loops labeled and colored differently from the rest of Fab. (D) Electrostatic potential 
surface of the antigen binding site of 10A37. Inset: The sequence of the peptide used for crystallization is 
shown, and residues observed in the electron density are shown in magenta.  
 
FIG 4. Antigen-antibody interactions of 10A37/V3JR-FL. (A) Hydrophilic interactions between the side 
chains of epitope and residues of 10A37. (B) Hydrophilic interactions between the main chains of the 
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epitope and residues of 10A37. (C) Schematic illustration of antigen-antibody interactions. The helix in 
the epitope is indicated by a pink shed. 
 
FIG 5. Structural comparison of rabbit V3 mAb complexes 10A3/V3ConB with R56/V3JR-FL. (A) 
Superimposition of the light chain variable domain structures of 10A3/V3ConB and R56/V3JR-FL (C 
RMSD = 0.32Å). 10A3 and its epitope are colored the same way as in Fig. 1. The light and heavy chains 
of R56 are colored in grey and its epitope is colored in orange. (B) Superimposition of the backbone 
structures of V3 epitopes bound to antibodies 10A3 and R56 with the side chains shown in sticks (C 
RMSD=0.92 Å). (C) Sequence alignment of the heavy (top) and light (bottom) chains of 10A3, R56 and 
their germlines. CDR1, 2, and 3 are indicated. Critical residues are indicated as shown in the legend.  
 
FIG 6. Structural comparison of rabbit V3 mAb complex 10A3/V3ConB with human V3 mAb complex and 
others encoded by IGHV5-51 germline genes. (A) Superimposition of the backbone structures of 
10A3/V3ConB and 2557/V3NY5 (C RMSD=0.94 Å). V3ConB and V3NY5 peptides are shown in magenta and 
red, respectively. 10A3 VL and VH are colored in cyan and green, while those of 2557 are colored in 
grey. Note that the V3 epitope bound in different orientations relative to the mAbs. (B) Superimposition 
of the peptides bound to 10A3 and 2557 with the side chains shown in sticks (C RMSD=1.58 Å). (C) 
Comparison of the V3 epitopes of rabbit and human mAbs. Plot showing the distribution and number of 
contact formed with the V3 loop by different mAbs. Squares containing letters indicate peptide 
differences from that complexed with 10A3, the sequence of which is shown above the grid. 
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Table 1. Crystallographic data collection and refinement statistics. 
 Fab 10A3/V3ConB Fab 10A37/V3JR-FL 
Data collection   
Space group P21221 P21 
Cell dimensions   
a, b, c (Å) 62.85, 83.87, 90.61 43.23, 173.90, 70.9142.16, 
170.38, 70.33 
, ,  90.00, 90.00, 90.00 90.00, 99.9798, 90.00 
Resolution (Å) 1.90 (2.01-1.90) 2.30 55 (2.4470-2.3055) 
CC (1/2) 100.0 (94.1) 99.8 6 (91.983.0) 
Rsym 6.5 (46.8) 7.610.0 (49.754.6) 
/ 31.1 (5.1) 15.611.9 (3.83.0) 
Completeness (%) 99.8 (98.8) 99.2 (98.6)99.6 (99.5) 
Redundancy 13.3 (10.4) 5.14.3 (5.14.3) 
Refinement   
Resolution (Å) 39.86-1.90 43.9244.61-2.5530 
Unique reflections 38,386 43,18833,251 
Rwork / Rfree 17.85/22.43 20.3761/26.5025.21 
No. atoms   
Protein 3,312 6,6256,622 
Solvent 668 223227 
Average B factors (Å2) 28.0 48.045.2 
r.m.s. deviations   
Bond lengths (Å) 0.006 0.008 
Bond angles (°) 0.855 0.9701.049 
PDB Code 5V6M 5V6L 
Statistics in parentheses refer to the outer resolution shell. 
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Table 2. Neutralizing activities of mAbs in a TZM-bl assay: IC50 (ug/ml)  
 
SF162 Ss1196 QH0692 Bx08.16 
W61D-
TCLA.71 
BaL.26 MW965.26 92BR025.9 
R56 0.1 7.18 8.6 3.18 ND 2.07 <0.02 ND 
10A3 0.05 5.51 ND 1.9 <0.01 1.06 <0.02 39.2 
ND: not determined. 
Adapted from Refs (15, 16). 
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